The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease

被引：30

作者：

Arita, Yoh ^{[1
]}

Sakata, Yasushi ^{[1
]}

Sudo, Takao ^{[2
]}

Maeda, Tetsuo ^{[2
]}

Matsuoka, Ken ^{[1
]}

Tamai, Keito ^{[1
]}

Higuchi, Kaori ^{[1
]}

Shioyama, Wataru ^{[1
]}

Nakaoka, Yoshikazu ^{[1
]}

Kanakura, Yuzuru ^{[2
]}

Yamauchi-Takihara, Keiko ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Suita, Osaka 5650871, Japan

[2] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan

来源：

HEART AND VESSELS | 2010年 / 25卷 / 05期

关键词：

Pulmonary arterial hypertension; Interleukin-6; Cytokine; receptor; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; RHEUMATOID-ARTHRITIS; INTERLEUKIN-6;

D O I：

10.1007/s00380-009-1215-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Castleman's disease is a highly heterogeneous clinical-pathological entity that belongs to the lymphoproliferative disorders and is associated with pulmonary arterial hypertension (PAH) in some patients. It is linked to excessive immune stimulation by interleukin-6 (IL-6), which is also involved in the pathogenesis of PAH. A 31-year-old woman with Castleman's disease demonstrated PAH characterized by severe right heart failure. Since she was resistant to various conventional therapies including steroids, prostacyclins, bosentan, and sildenafil, tocilizumab (anti-IL-6 receptor antibody) therapy was started. Her clinical course was followed for 6 months, with significant improvement without any adverse effect. This is the first reported case of use of tocilizumab in addition to steroids and conventional PAH therapy in a patient with PAH associated with Castleman's disease.

引用

页码：444 / 447

页数：4

共 19 条

[1] ALLEVIATION OF SYSTEMIC MANIFESTATIONS OF CASTLEMANS DISEASE BY MONOCLONAL ANTI-INTERLEUKIN-6 ANTIBODY [J].

BECK, JT ;

HSU, SM ;

WIJDENES, J ;

BATAILLE, R ;

KLEIN, B ;

VESOLE, D ;

HAYDEN, K ;

JAGANNATH, S ;

BARLOGIE, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :602-605

[2] Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8 [J].

Bull, TM ;

Cool, CD ;

Serls, AE ;

Rai, PR ;

Parr, J ;

Neid, JM ;

Geraci, MW ;

Campbell, TB ;

Voelkel, NF ;

Badesch, DB .

EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (03) :403-407

[3] ATS statement: Guidelines for the six-minute walk test [J].

Crapo, RO ;

Casaburi, R ;

Coates, AL ;

Enright, PL ;

MacIntyre, NR ;

McKay, RT ;

Johnson, D ;

Wanger, JS ;

Zeballos, RJ ;

Bittner, V ;

Mottram, C .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (01) :111-117

[4] The clinical behavior of localized and multicentric Castleman disease [J].

Herrada, J ;

Cabanillas, F ;

Rice, L ;

Manning, J ;

Pugh, W .

ANNALS OF INTERNAL MEDICINE, 1998, 128 (08) :657-662

[5] INCREASED INTERLEUKIN-1 AND INTERLEUKIN-6 SERUM CONCENTRATIONS IN SEVERE PRIMARY PULMONARY-HYPERTENSION [J].

HUMBERT, M ;

MONTI, G ;

BRENOT, F ;

SITBON, O ;

PORTIER, A ;

GRANGEOTKEROS, L ;

DUROUX, P ;

GALANAUD, P ;

SIMONNEAU, G ;

EMILIE, D .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 151 (05) :1628-1631

[6] Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats [J].

Ito, Takayuki ;

Okada, Takashi ;

Miyashita, Hiroshi ;

Nomoto, Tatsuya ;

Nonaka-Sarukawa, Mutsuko ;

Uchibori, Ryosuke ;

Maeda, Yoshikazu ;

Urabe, Masashi ;

Mizukami, Hiroaki ;

Kume, Akihiro ;

Takahashi, Masafumi ;

Ikeda, Uichi ;

Shimada, Kazuyuki ;

Ozawa, Keiya .

CIRCULATION RESEARCH, 2007, 101 (07) :734-741

[7] Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease [J].

Montani, D ;

Achouh, L ;

Marcelin, AG ;

Viard, JP ;

Hermine, O ;

Canioni, D ;

Sitbon, O ;

Simonneau, G ;

Humbert, M .

EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (05) :969-972

[8] Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension [J].

Nagaya, N ;

Uematsu, M ;

Satoh, T ;

Kyotani, S ;

Sakamaki, F ;

Nakanishi, N ;

Yamagishi, M ;

Kunieda, T ;

Miyatake, K .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (02) :487-492

[9] Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial [J].

Nishimoto, N ;

Yoshizaki, K ;

Miyasaka, N ;

Yamamoto, K ;

Kawai, S ;

Takeuchi, T ;

Hashimoto, J ;

Azuma, J ;

Kishimoto, T .

ARTHRITIS AND RHEUMATISM, 2004, 50 (06) :1761-1769

[10] Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease [J].

Nishimoto, N ;

Kanakura, Y ;

Aozasa, K ;

Johkoh, T ;

Nakamura, M ;

Nakano, S ;

Nakano, N ;

Ikeda, Y ;

Sasaki, T ;

Nishioka, K ;

Hara, M ;

Taguchi, H ;

Kimura, Y ;

Kato, Y ;

Asaoku, H ;

Kumagai, S ;

Kodama, F ;

Nakahara, H ;

Hagihara, K ;

Yoshizaki, K ;

Kishimoto, T .

BLOOD, 2005, 106 (08) :2627-2632

← 1 2 →